Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.
Znaor A, Skakkebaek NE, Rajpert-De Meyts E, Laversanne M, Kuliš T, Gurney J, et al. Testicular cancer incidence predictions in Europe 2010-2035: a rising burden despite population ageing. Int J Cancer. 2020;147:820–8.
Gurney JK, Florio AA, Znaor A, Ferlay J, Laversanne M, Sarfati D, et al. International trends in the incidence of testicular cancer: lessons from 35 years and 41 countries. Eur Urol. 2019;76:615–23.
Rajpert-De Meyts E, McGlynn KA, Okamoto K, Jewett MA, Bokemeyer C. Testicular germ cell tumours. Lancet. 2016;387:1762–74.
Pluta J, Pyle LC, Nead KT, Wilf R, Li M, Mitra N, et al. Identification of 22 susceptibility loci associated with testicular germ cell tumors. Nat Commun. 2021;12:4487.
Cook MB, Akre O, Forman D, Madigan MP, Richiardi L, McGlynn KA. A systematic review and meta-analysis of perinatal variables in relation to the risk of testicular cancer-experiences of the son. Int J Epidemiol. 2010;39:1605–18.
McGlynn KA, Trabert B. Adolescent and adult risk factors for testicular cancer. Nat Rev Urol. 2012;9:339–49.
Ghasemiesfe M, Barrow B, Leonard S, Keyhani S, Korenstein D. Association between marijuana use and risk of cancer: a systematic review and meta-analysis. JAMA Netw Open. 2019;2:e1916318.
Skakkebaek NE, Rajpert-De Meyts E, Main KM. Testicular dysgenesis syndrome: an increasingly common developmental disorder with environmental aspects. Hum Reprod. 2001;16:972–8.
Hoei-Hansen CE, Rajpert-De Meyts E, Daugaard G, Skakkebaek NE. Carcinoma in situ testis, the progenitor of testicular germ cell tumours: a clinical review. Ann Oncol. 2005;16:863–8.
Chen J, Sørensen HT, Miao M, Liang H, Ehrenstein V, Wang Z, et al. Cryptorchidism and increased risk of neurodevelopmental disorders. J Psychiatr Res. 2018;96:153–61.
Butwicka A, Lichtenstein P, Landén M, Nordenvall AS, Nordenström A, Nordenskjöld A, et al. Hypospadias and increased risk for neurodevelopmental disorders. J Child Psychol Psychiatry. 2015;56:155–61.
Huang J, Zhu T, Qu Y, Mu D. Prenatal, perinatal and neonatal risk factors for intellectual disability: a systemic review and meta-analysis. PLoS ONE. 2016;11:e0153655.
Carlsson T, Molander F, Taylor MJ, Jonsson U, Bölte S. Early environmental risk factors for neurodevelopmental disorders – a systematic review of twin and sibling studies. Dev Psychopathol. 2021:33:1448–95.
Liu KX, Sethi RV, Pulsifer MB, D’Gama AM, LaVally B, Ebb DH, et al. Clinical outcomes of pediatric patients with autism spectrum disorder and other neurodevelopmental disorders and intracranial germ cell tumors. Pediatr Blood Cancer. 2021;68:e28935.
Mortensen PB. The occurrence of cancer in first admitted schizophrenic patients. Schizophr Res. 1994;12:185–94.
Kaerlev L, Iachina M, Trosko O, Qvist N, Ljungdalh PM, Nørgård BM. Colon cancer patients with a serious psychiatric disorder present with a more advanced cancer stage and receive less adjuvant chemotherapy – a nationwide Danish cohort study. BMC Cancer. 2018;18:1050.
Shinden Y, Kijima Y, Hirata M, Nakajo A, Tanoue K, Arigami T, et al. Clinical characteristics of breast cancer patients with mental disorders. Breast. 2017;36:39–43.
Kishimoto N, Takao T, Tsutahara K, Tanigawa G, Yamaguchi S. Clinical analysis of severe psychiatric disorders in patients with testicular cancer: a single-center experience. Int J Urol. 2016;23:626–7.
Thapar A, Cooper M, Rutter M. Neurodevelopmental disorders. Lancet Psychiatry. 2017;4:339–46.
Peckham MJ, McElwain TJ, Barrett A, Hendry WF. Combined management of malignant teratoma of the testis. Lancet. 1979;2:267–70.
Tandstad T, Ståhl O, Håkansson U, Wahlqvist R, Klepp O, Cavallin-Ståhl E, et al. The SWENOTECA group: a good example of continuous binational and multidisciplinary collaboration for patients with testicular cancer in Sweden and Norway. Scand J Urol. 2016;50:9–13.
Plant AS, Chi SN, Frazier L. Pediatric malignant germ cell tumors: a comparison of the neuro-oncology and solid tumor experience. Pediatr Blood Cancer. 2016;63:2086–95.
Liu Q, Yin W, Meijsen JJ, Reichenberg A, Gådin JR, Schork AJ, et al. Cancer risk in individuals with autism spectrum disorder. Ann Oncol. 2022;33:713–9.
Trabert B, Zugna D, Richiardi L, McGlynn KA, Akre O. Congenital malformations and testicular germ cell tumors. Int J Cancer. 2013;133:1900–4.
Daltveit DS, Klungsøyr K, Engeland A, Ekbom A, Gissler M, Glimelius I, et al. Cancer risk in individuals with major birth defects: large Nordic population based case-control study among children, adolescents, and adults. BMJ. 2020;371:m4060.
Thapar A, Cooper M. Attention deficit hyperactivity disorder. Lancet. 2016;387:1240–50.
Chaste P, Leboyer M. Autism risk factors: genes, environment, and gene-environment interactions. Dialog Clin Neurosci. 2012;14:281–92.
Crawley JN, Heyer WD, LaSalle JM. Autism and cancer share risk genes, pathways, and drug targets. Trends Genet. 2016;32:139–46.
Crespi B. Autism and cancer risk. Autism Res. 2011;4:302–10.
Borrie SC, Brems H, Legius E, Bagni C. Cognitive dysfunctions in intellectual disabilities: the contributions of the Ras-MAPK and PI3K-AKT-mTOR pathways. Annu Rev Genomics Hum Genet. 2017;18:115–42.
Ichimura K, Fukushima S, Totoki Y, Matsushita Y, Otsuka A, Tomiyama A, et al. Recurrent neomorphic mutations of MTOR in central nervous system and testicular germ cell tumors may be targeted for therapy. Acta Neuropathol. 2016;131:889–901.
McIntyre A, Gilbert D, Goddard N, Looijenga L, Shipley J. Genes, chromosomes and the development of testicular germ cell tumors of adolescents and adults. Genes Chromosomes Cancer. 2008;47:547–57.
Giannandrea F, Paoli D, Figà-Talamanca I, Lombardo F, Lenzi A, Gandini L. Effect of endogenous and exogenous hormones on testicular cancer: the epidemiological evidence. Int J Dev Biol. 2013;57:255–63.
Romano E, Cosentino L, Laviola G, De Filippis B. Genes and sex hormones interaction in neurodevelopmental disorders. Neurosci Biobehav Rev. 2016;67:9–24.
Lymperi S, Giwercman A. Endocrine disruptors and testicular function. Metabolism. 2018;86:79–90.
Bräuner EV, Lim YH, Koch T, Uldbjerg CS, Gregersen LS, Pedersen MK, et al. Endocrine disrupting chemicals and risk of testicular cancer a systematic review and meta-analysis. J Clin Endocrinol Metab. 2021;106:e4834–60.
Rivollier F, Krebs MO, Kebir O. Perinatal exposure to environmental endocrine disruptors in the emergence of neurodevelopmental psychiatric diseases: a systematic review. Int J Environ Res Public Health. 2019;16:1318.
Tabarés-Seisdedos R, Dumont N, Baudot A, Valderas JM, Climent J, Valencia A, et al. No paradox, no progress: inverse cancer comorbidity in people with other complex diseases. Lancet Oncol. 2011;12:604–8.
Ji J, Sundquist K, Ning Y, Kendler KS, Sundquist J, Chen X. Incidence of cancer in patients with schizophrenia and their first-degree relatives: a population-based study in Sweden. Schizophr Bull. 2013;39:527–36.
Tabarés-Seisdedos R, Rubenstein JL. Chromosome 8p as a potential hub for developmental neuropsychiatric disorders: implications for schizophrenia, autism and cancer. Mol Psychiatry. 2009;14:563–89.
Enriquez-Barreto L, Morales M. The PI3K signaling pathway as a pharmacological target in autism related disorders and schizophrenia. Mol Cell Ther. 2016;4:2.
Li H, Li J, Yu X, Zheng H, Sun X, Lu Y, et al. The incidence rate of cancer in patients with schizophrenia: a meta-analysis of cohort studies. Schizophr Res. 2018;195:519–28.
McGlynn KA, Cook MB. Etiologic factors in testicular germ-cell tumors. Future Oncol. 2009;5:1389–402.
Bray F, Richiardi L, Ekbom A, Forman D, Pukkala E, Cuninkova M, et al. Do testicular seminoma and nonseminoma share the same etiology? Evidence from an age-period-cohort analysis of incidence trends in eight European countries. Cancer Epidemiol Biomark Prev. 2006;15:652–8.
Chesney E, Goodwin GM, Fazel S. Risks of all-cause and suicide mortality in mental disorders: a meta-review. World Psychiatry. 2014;13:153–60.
Chang WH, Lai AG. Cumulative burden of psychiatric disorders and self-harm across 26 adult cancers. Nat Med. 2022;28:860–70.
Giacobini M, Medin E, Ahnemark E, Russo LJ, Carlqvist P. Prevalence, patient characteristics, and pharmacological treatment of children, adolescents, and adults diagnosed with ADHD in Sweden. J Atten Disord. 2018;22:3–13.
Idring S, Lundberg M, Sturm H, Dalman C, Gumpert C, Rai D, et al. Changes in prevalence of autism spectrum disorders in 2001-2011: findings from the Stockholm youth cohort. J Autism Dev Disord. 2015;45:1766–73.